CFAs: New Mechanisms and Emerging Treatment Options in Metastatic Castration-Resistant Prostate Cancer

Deadline: 21-Oct-2026

Pfizer is inviting eligible organizations to submit proposals for independent medical education projects focused on metastatic castration-resistant prostate cancer (mCRPC). Individual projects can receive between $75,000 and $250,000, supporting initiatives that improve healthcare professionals’ understanding of emerging treatment options, new mechanisms of disease, and innovative therapeutic approaches.

About the Pfizer mCRPC Medical Education Grant

This grant program addresses the continuing unmet need for novel therapies in metastatic castration-resistant prostate cancer. The program supports independent medical education initiatives designed to increase healthcare professional awareness and understanding of emerging developments in mCRPC. A particular area of interest is the development and understanding of therapies involving EZH2 inhibition, as well as other innovative approaches to treating mCRPC. The program is intended to support educational projects that provide healthcare professionals with relevant, evidence-based information about emerging mechanisms and treatment strategies. What Does the Grant Support? Proposed projects should improve healthcare professionals’ awareness and understanding of: - New mechanisms of disease in mCRPC - Emerging treatment options - Differentiated mechanisms of action of emerging therapies - EZH2 inhibition - Androgen receptor (AR) inhibition - The investigational thesis of concomitant EZH2 and AR inhibition - Therapies beyond chemotherapy - Ongoing clinical trials relevant to mCRPC - Innovative therapeutic approaches Projects should focus on meaningful medical education rather than simply promoting individual products or treatments. Focus on Emerging Treatment Mechanisms A key objective of the grant is to help healthcare professionals understand how emerging therapies may work differently from existing treatment approaches. Educational initiatives can examine differentiated mechanisms of action and explain how emerging therapeutic strategies could potentially address unmet needs in mCRPC. The goal is to improve healthcare professionals’ understanding of the evolving treatment landscape. EZH2 and AR Inhibition The grant specifically identifies the investigational thesis of concomitant EZH2 and androgen receptor (AR) inhibition as an area of educational interest. Projects may help healthcare professionals understand the scientific rationale behind this approach and its potential relevance to the treatment of mCRPC. Because this is an emerging and investigational area, educational content should appropriately distinguish established evidence from ongoing research and clinical investigation. Therapies Beyond Chemotherapy Another area of interest is education on treatment approaches that extend beyond traditional chemotherapy. Projects should help healthcare professionals understand emerging therapeutic strategies and how new mechanisms may contribute to the evolving mCRPC treatment landscape. Clinical Trials in mCRPC Proposals can also focus on ongoing clinical trials relevant to metastatic castration-resistant prostate cancer. Educational activities may help healthcare professionals understand: - Current clinical research - Investigational therapies - Emerging mechanisms - Clinical trial evidence - The potential implications of ongoing research for future treatment strategies Who Can Apply? The grant is open to eligible organizations based in the United States or Europe.

Eligible organizations include:

- Medical schools - Dental schools - Nursing schools - Allied health professional schools - Pharmacy schools - Healthcare institutions - Professional organizations - Medical societies - Medical education companies - Other organizations with a mission related to healthcare professional education or improvement Only organizations are eligible to receive grants. Who Is Not Eligible? Individuals cannot apply directly for funding under this opportunity. Unaffiliated medical practice groups are also not eligible to receive grants. Applicants should therefore ensure that the requesting organization meets the program’s organizational eligibility requirements before preparing a proposal. Accreditation Requirement for Continuing Education Organizations proposing projects that provide continuing education credit must be appropriately accredited. Applicants should confirm that the requesting organization has the required accreditation before proposing an accredited continuing education activity. Funding Available

Individual projects can request between:

- $75,000 minimum - $250,000 maximum The total estimated budget available under this request for proposals is $750,000. The requested amount should be appropriate to the scope, duration and educational objectives of the proposed project. What Costs Can the Grant Cover?

Award amounts may include:

- Direct project costs - Institutional overhead - Indirect costs Institutional overhead is capped at 28%. Applicants should develop their budgets carefully and ensure that proposed costs are directly connected to the educational project. Project Duration The maximum project length is 18–24 months. Applicants should establish a realistic implementation timeline that allows sufficient time to develop, deliver and evaluate the proposed medical education activities. What Makes a Strong Proposal? A strong proposal should clearly demonstrate an educational need among healthcare professionals working with patients with mCRPC.

Applicants should explain:

- The specific educational gap - The target healthcare professional audience - Why the topic is clinically relevant - What emerging mechanisms or therapies will be addressed - How the project will improve professional knowledge or understanding - How the educational activities will address the identified gap - How learning outcomes will be evaluated - Why the proposed educational format is appropriate The proposal should establish a clear connection between th